Advanced Surgery Advantage
A data-driven, evidence-based haemostasis optimisation programme
The Burden of Bleeding
30%
Average rate of bleeding complications during surgery1
6 Days
Length of stay associated with bleeding-related complications or transfusions1
£10K+
Potential incremental cost of bleeding complications per patient hospitalisation for major surgeries1
The Challenge of Surgical Bleeding
Surgical bleeding can lead to complications and increased allogeneic blood utilisation creating headwinds to meeting your performance measures.
Surgical bleeds are associated with increased complication rates in1:
● Surgical revisions
● Transfusions
● Length of stay
● Increased resource utilisation
Focus on blood management protocols emphasising intraoperative interventions, including use of topical haemostatic agents, can help mitigate these challenges.
What Is Advanced Surgery Advantage?
Advanced Surgery Advantage is a data-driven, evidence-based haemostasis optimisation programme. It supports hospital initiatives aimed at:
● Reducing intraoperative blood loss
● Reducing blood transfusions
● Optimising patient outcomes after surgery
● Reducing waste
● Cost avoidance
It provides an approach to partnering with hospitals in support of their goals and quality initiatives.
Efficiencies in the Operating Room
Through Advanced Surgery Advantage, Baxter’s Advanced Surgery team partners with hospitals in support of their goals and quality programs. Advanced Surgery Advantage provides actionable insights and practical solutions related to intraoperative haemostasis that will help healthcare providers realise marked improvements in three, interconnected areas of surgical care:
● Clinical efficacy
● Financial performance
● Operational efficiency
Advanced Surgery Advantage offers several potential collaboration opportunities
Live Utilisation Review
To help hospitals assess their current state of haemostat utilisation, Baxter conducts unbiased observation reviews of haemostat and sealant use, resulting in a detailed report of findings and improvement opportunities.
Health Economic Assessment
To help hospitals quantify potential efficiency savings, Baxter works with hospitals to create a model to assess potential savings and measure results after implementing process improvement opportunities.
Patient Blood Management
To help hospitals assess the impact of implementing an intraoperative haemostasis protocol to reduce transfusions, Baxter supports the operating room surgical team in identifying clinical endpoints and evaluation criteria to measure the success of improvement initiatives.
Portfolio of Products
Prescribing Information:
 |
UK TISSEEL | |
UK ARTISS |
Adverse Events and any drug or medical device product quality complaints (including suspected defective medicines or medical device adverse incidents) should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse Event and Product Complaint Handling
Adverse Events should also be reported to Baxter Healthcare Ltd, by email ([email protected]) or by phone (+44) 01635 260360
Drug or medical device product quality complaints relating to Baxter products can be reported directly to Baxter Healthcare Ltd by email ([email protected]) or by phone (+44 1604 704603).